Vitamin D receptor genetic polymorphisms and prostate cancer risk: A meta-analysis of 36 published studies

International Journal of Clinical and Experimental Medicine

Volumn 2, Issue 2, 2009, Pages 159-175

  Yin, Ming ^a   Wei, Sheng ^a   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Genetic polymorphism; Meta analysis; Molecular epidemiology; Prostate cancer

Indexed keywords

APAL PROTEIN; BIOLOGICAL MARKER; BSML PROTEIN; FOKL PROTEIN; TAQL PROTEIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VITAMIN RECEPTOR;

ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; DATA BASE; ETHNICITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MALE; METHODOLOGY; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 67749086863     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH and Orentreich N. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2: 467-472.
3. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA and Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 805-810.
4. Skowronski RJ, Peehl DM and Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-1960.
5. Hanchette CL and Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992; 70: 2861-2869.
6. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE and Upadhya P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992; 52: 515-520.
7. Towsend K, Trevino V, Falciani F, Stewart PM, Hewison M and Campbell MJ. Identification of VDR-responsive gene signatures in breast cancer cells. Oncology 2006; 71: 111-123.
8. Campbell MJ, Gombart AF, Kwok SH, Park S and Koeffler HP. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 2000; 19: 5091-5097.
9. Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, Inoue Y, Morita K, Takeda E and Pike JW. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997; 11: 1165-1179.
10. Crofts LA, Hancock MS, Morrison NA and Eisman JA. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci U S A 1998; 95: 10529-10534.
11. Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R and Feldman D. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 1996; 11: 1850-1855.
12. Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY and Feldman D. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res 1998; 13: 1691-1699.
13. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, Kubota M, Yoshida S, Ikeda M, Watabe F, Kanemasa Y and Takeda E. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 2001; 16: 1256-1264.
14. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S and Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1990-1999.
15. Hayes VM, Severi G, Padilla EJ, Eggleton SA, Southey MC, Sutherland RL, Hopper JL and Giles GG. Genetic variants in the vitamin D receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 997-999.
16. Ntais C, Polycarpou A and Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 1395-1402.
17. Berndt SI, Dodson JL, Huang WY and Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 2006; 175: 1613-1623.
18. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
19. Lau J, Ioannidis JP and Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
20. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F and Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248-254.
21. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj 1997; 315: 629-634.
22. Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA and Strange RC. Outcome in prostate cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis 2001; 22: 1343-1347.
23. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Koike H, Nakazato H, Okugi H, Hasumi M, Fukabori Y, Kurokawa K and Yamanaka H. Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol 2003; 10: 261-266.
24. Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B and Thammavit W. Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac J Cancer Prev 2006; 7: 136-139.
25. Furuya Y, Akakura K, Masai M and Ito H. Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer. Endocr J 1999; 46: 467-470.
26. Blazer DG, 3rd, Umbach DM, Bostick RM and Taylor JA. Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinog 2000; 27: 18-23.
27. Watanabe M, Fukutome K, Murata M, Uemura H, Kubota Y, Kawamura J and Yatani R. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res 1999; 19: 4511-4514.
28. Huang SP, Chou YH, Wayne Chang WS, Wu MT, Chen YY, Yu CC, Wu TT, Lee YH, Huang JK, Wu WJ and Huang CH. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004; 207: 69-77.
29. Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z and Ostrander EA. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004; 59: 409-418.
30. Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M and Narod SA. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 1429-1437.
31. Onen IH, Ekmekci A, Eroglu M, Konac E, Yesil S and Biri H. Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer. Exp Biol Med (Maywood) 2008; 233: 1608-1614.
32. Oakley-Girvan I, Feldman D, Eccleshall TR, Gallagher RP, Wu AH, Kolonel LN, Halpern J, Balise RR, West DW, Paffenbarger RS, Jr. and Whittemore AS. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev 2004; 13: 1325-1330.
33. Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Baron AE, Lucia MS, Thompson IM and Leach RJ. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res 2008; 14: 3223-3229.
34. John EM, Schwartz GG, Koo J, Van Den Berg D and Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005; 65: 5470-5479.
35. Maistro S, Snitcovsky I, Sarkis AS, da Silva IA and Brentani MM. Vitamin D receptor polymorphisms and prostate cancer risk in Brazilian men. Int J Biol Markers 2004; 19: 245-249.
36. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI and McLeod HL. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Saudi Med J 2004; 25: 447-451.
37. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, Ogawa O and Kato T. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000; 60: 305-308.
38. Boyle P, Severi G and Giles GG. The epidemiology of prostate cancer. Urol Clin North Am 2003; 30: 209-217.
39. Wolk A. Diet, lifestyle and risk of prostate cancer. Acta Oncol 2005; 44: 277-281.
40. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL and Ma J. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007; 4: e103.
41. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM and Hayes RB. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 2008; 100: 796-804.
42. Gandini S, Raimondi S, Gnagnarella P, Dore JF, Maisonneuve P and Testori A. Vitamin D and skin cancer: A meta-analysis. Eur J Cancer 2008;
43. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN and Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284-287.
44. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, Haussler CA, Galligan MA, Thatcher ML, Encinas Dominguez C and Haussler MR. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 2001; 177: 145-159.
45. Schatzl G, Gsur A, Bernhofer G, Haidinger G, Hinteregger S, Vutuc C, Haitel A, Micksche M, Marberger M and Madersbacher S. Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urology 2001; 57: 567-572.
46. Bousema JT, Bussemakers MJ, van Houwelingen KP, Debruyne FM, Verbeek AL, de La Rosette JJ and Kiemeney LA. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol 2000; 37: 234-238.
47. Hamasaki T, Inatomi H, Katoh T, Ikuyama T and Matsumoto T. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int 2002; 68: 226-231.
48. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW and Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 2007; 67: 911-923.
49. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH and Hunter DJ. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998; 7: 385-390.
50. Davis CD. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr 2008; 88: 565S-569S.
51. Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN and Goltzman D. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279: 16754-16766.
52. Valrance ME and Welsh J. Breast cancer cell regulation by high-dose Vitamin D compounds in the absence of nuclear vitamin D receptor. J Steroid Biochem Mol Biol 2004; 89-90: 221-225.
53. Kibel AS, Isaacs SD, Isaacs WB and Bova GS. Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol 1998; 160: 1405-1409.
54. Correa-Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O and Vogel W. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 1999; 105: 281-287.
55. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W and Haile RW. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998; 58: 1620-1623.
56. Cicek MS, Liu X, Schumacher FR, Casey G and Witte JS. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 2549-2552.
57. Duval S and Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.